Method of nitrous oxide delivery in patients requiring surgery under general anaesthetic. Surgery
Conditions
Interventions
The NOBLE trial will have two distinct phases each lasting 5 weeks. Hospitals will be randomised 1:1 either to a control phase (pipeline nitrous oxide supply) followed by an intervention phase (cylind
Sponsors
University of Birmingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients (adults and children) undergoing surgery under general anaesthesia in participating hospitals (regardless of exposure to nitrous oxide anaesthesia)
Exclusion criteria
Exclusion criteria: Patients who have opted out of anonymous data sharing Patients undergoing repeat surgery within 30 days after a procedure recorded in the NOBLE trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Days Alive and At Home Within 30 Days after surgery (DAH30). The day of surgery is defined as day zero. Patients who die within 30 days after surgery will be given a value of zero. DAH30 data will be collected from routine data in patient health records by local investigators who are members of the direct care team. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Use of nitrous oxide anaesthesia during surgery (Y/N) 2. Mortality within 30 days after surgery 3. Major complications during surgery (Clavien-Dindo grade =III) 4. Duration of hospital stay (days) 5. NHS costs of nitrous oxide provision All secondary outcome measures will be collected from routine hospital records at 30 days after surgery | — |
Countries
England, Scotland, United Kingdom, Wales
Contacts
Public ContactRachel Lillywhite
Outcome results
None listed